2.11

1.93% 0.04

Vistagen Therapeutics Inc (VTGN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Vistagen Therapeutics Inc stock is traded at $2.11, with a volume of 70,628. It is up +1.93% in the last 24 hours and down -25.04% over the past month. Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Previous Close:

$2.07

Open:

$2.07

24h Volume:

70,628

Relative Volume:

0.47

Market Cap:

$64.36M

Revenue:

$875.70K

Net Income/Loss:

$-39.57M

P/E Ratio:

-1.5719

EPS:

-1.3423

Net Cash Flow:

$-33.65M

1W Performance:

+2.93%

1M Performance:

-25.04%

6M Performance:

-31.05%

1Y Performance:

-54.82%

1-Day Range:

$2.00

$2.125

1-Week Range:

$1.965

$2.32

52-Week Range:

$1.90

$5.00

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Name

Vistagen Therapeutics Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

650-577-3600

Address

343 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Employee

Twitter

@vistagen

Next Earnings Date

2024-11-07

Latest SEC Filings

VTGN's Discussions on Twitter

Compare VTGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VTGN Vistagen Therapeutics Inc	2.11	64.36M	875.70K	-39.57M	-33.65M	-1.3423
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-07-23	Upgrade	Jefferies	Hold → Buy
Aug-07-23	Upgrade	Maxim Group	Hold → Buy
Jul-22-22	Downgrade	Jefferies	Buy → Hold
Jul-22-22	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-22-22	Downgrade	William Blair	Outperform → Mkt Perform
May-20-21	Initiated	Robert W. Baird	Outperform
Feb-18-21	Initiated	Jefferies	Buy
Jan-04-21	Upgrade	William Blair	Mkt Perform → Outperform
Jun-27-18	Initiated	Maxim Group	Buy
Feb-08-18	Reiterated	Chardan Capital Markets	Buy
Mar-28-17	Initiated	Maxim Group	Buy

View All

Vistagen Therapeutics Inc Stock (VTGN) Latest News

Apr 17, 2025

Social Anxiety Crisis: 48% of Young Adults Report Suicidal Thoughts, Treatment Gap Widens - Stock Titan

Apr 17, 2025

Apr 08, 2025

Financial Survey: Vistagen Therapeutics (NASDAQ:VTGN) versus IO Biotech (NASDAQ:IOBT) - Defense World

Apr 08, 2025

Apr 06, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Purchased by Blair William & Co. IL - Defense World

Apr 06, 2025

Apr 04, 2025

VTGN Stock Touches 52-Week Low at $2.21 Amid Market Challenges - Investing.com UK

Apr 04, 2025

Apr 03, 2025

VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019 - ACCESS Newswire

Apr 03, 2025

Mental Disorder Treatment Market Set to Witness Significant - openPR.com

Apr 03, 2025

Mar 24, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above Fifty Day Moving AverageHere's Why - MarketBeat

Mar 24, 2025

Mar 21, 2025

Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR.com

Mar 21, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50-Day Moving Average – Should You Sell? - Defense World

Mar 21, 2025

Mar 19, 2025

Vistagen to Present at the 2025 Anxiety and Depression Association Conference - Sharewise

Mar 19, 2025

Groundbreaking Social Anxiety Treatment Research: Vistagen Reveals New Clinical Data at ADAA 2025 - StockTitan

Mar 19, 2025

Mar 14, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Below 50 Day Moving AverageTime to Sell? - MarketBeat

Mar 14, 2025

Mar 12, 2025